BPA for pluvicto and lutathera injection
Active Blanket Purchase Agreement Awarded Last action
- Contract number
- HT941026AE002
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Task orders
- 3 $578,816 obligated
Award facts
- Combined order value
- $578,816 Current and potential, with all options
- Last date to order 13% complete
- IDV ceiling 12% used
- $5,000,000.00
- Maximum order
- $500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement was awarded by the Defense Health Agency to Novartis Pharmaceuticals Corporation on March 2, 2026, as a single-award indefinite delivery vehicle with a ceiling value of $5.0 million and a performance period extending through February 9, 2031. The contract authorizes the procurement of two specialized radiopharmaceutical cancer therapies: PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). Both products represent advanced targeted nuclear medicine treatments used in oncology applications, specifically for patients with castration-resistant prostate cancer and neuroendocrine tumors, respectively. As a large pharmaceutical manufacturer, Novartis competes directly in the federal marketplace without small business set-aside protections. The contract operates under firm fixed-price delivery orders, enabling the Defense Health Agency to issue calls against the established ceiling as healthcare needs arise across its beneficiary population.
Performance of this contract is executed from Novartis' multiple manufacturing and distribution facilities, including locations in East Hanover, New Jersey; Lake Mary, Florida; Phoenix, Arizona; Lebanon, Pennsylvania; Cary, North Carolina; Chicago, Illinois; San Antonio, Texas; and West Haven, Connecticut. This geographic distribution of performance locations supports Novartis' capacity to fulfill delivery orders for radiopharmaceutical products with appropriate quality assurance and logistics management across the federal healthcare system. The contract structure aligns with the Defense Health Agency's procurement strategy for specialized oncology pharmaceuticals and complements additional indefinite delivery vehicles Novartis maintains with the Veterans Integrated Service Networks, consolidating the contractor's role as a primary supplier of innovative cancer therapies to the Department of Defense health system and veteran care programs.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| BPA for pluvicto and lutathera injection | Defense Health Agency | $205,766 | |
| Pluvicto and lutathera injections | Defense Health Agency | $167,285 | |
| Pluvicto and lutathera injection | Defense Health Agency | $205,766 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HT941026AE002?
HT941026AE002 was awarded to Novartis Pharmaceuticals Corporation by Defense Health Agency (Department of Defense) on March 2, 2026.
How much is contract HT941026AE002 worth?
Orders under HT941026AE002 have obligated $578,816. HT941026AE002's own ceiling is $5,000,000. A single order can be worth up to $500,000.
How many orders have been placed under contract HT941026AE002?
3 orders have been placed under HT941026AE002, the latest on July 21, 2026.
Who can order from contract HT941026AE002?
HT941026AE002 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV